Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer
Public ClinicalTrials.gov record NCT00209092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase II Trial of Sequential Docetaxel Followed by Capecitabine Versus Concomitant, Dose-Dense Docetaxel/Capecitabine as in Induction Therapy for Early Stage Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
Study identification
- NCT ID
- NCT00209092
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 51 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2006
- Primary completion
- Jun 30, 2009
- Completion
- Sep 30, 2012
- Last update posted
- Mar 26, 2015
2006 – 2012
United States locations
- U.S. sites
- 19
- U.S. states
- 1
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Grady Memorial Hospital | Atlanta | Georgia | 30303 | — |
| Emory Crawford Long Hospital | Atlanta | Georgia | 30308 | — |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Augusta Oncology Associates, PC 1348 Walton Way, Ste. 4300 | Augusta | Georgia | 30901 | — |
| Augusta Oncology Associates, PC 3696 Wheeler Road | Augusta | Georgia | 30909 | — |
| WellStar Health System-Georgia Cancer Specialists | Austell | Georgia | 30106 | — |
| WellStar Health System-Northwest Georgia Oncology Center, PC | Austell | Georgia | 30106 | — |
| WellStar Health System-Northwest Georgia Oncology Center, PC | Carrollton | Georgia | 30117 | — |
| John B. Amos Cancer Center | Columbus | Georgia | 31904 | — |
| Suburban Hematology-Oncology Associates, PC | Duluth | Georgia | 30096 | — |
| South Atlanta Hematology-Oncology Group | East Point | Georgia | 30344 | — |
| Suburban Hematology-Oncology Associates, PC | Lawrenceville | Georgia | 30045 | — |
| Central Georgia Cancer Care, PC | Macon | Georgia | 31201 | — |
| WellStar Health System-Georgia Cancer Specialists | Marietta | Georgia | 30060 | — |
| WellStar Health System-Northwest Georgia Oncology Center, PC | Marietta | Georgia | 30060 | — |
| South Atlanta Hematology-Oncology Group | Riverdale | Georgia | 30274 | — |
| Suburban Hematology-Oncology Associates, PC | Snellville | Georgia | 30078 | — |
| South Atlanta Hematology-Oncology Group | Stockbridge | Georgia | 30281 | — |
| Central Georgia Cancer Care, PC | Warner Robins | Georgia | 31093 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00209092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2015 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00209092 live on ClinicalTrials.gov.